Le Lézard
Classified in: Health
Subject: STP

Department of Health Releases 12 Medical Marijuana Permits for Growers/Processors


HARRISBURG, Pa., June 20, 2017 /PRNewswire-USNewswire/ -- The Pennsylvania Department of Health today released information on the issuance of 12 permits for medical marijuana growers/processors in the state. The permittees will now have six months in which to become operational before they can begin growing medical marijuana. Entities receiving permits were notified by mail.

"With today's announcement, we remain on track to fulfill the Wolf Administration's commitment to deliver medical marijuana to patients in 2018," said John Collins, Director of the Office of Medical Marijuana. "The applications from the entities receiving permits were objectively reviewed by an evaluation team made up of members from across commonwealth agencies. Any letters of recommendation or support for an applicant were not considered during the evaluation."

The 12 permits were issued to:

Southeast Region
Prime Wellness of Pennsylvania, LLC
Franklin Labs, LLC

Northeast Region
Pennsylvania Medical Solutions, LLC
Standard Farms, LLC

Southcentral Region
Ilera Healthcare, LLC
AES Compassionate Care, LLC

Northcentral Region
Terrapin Investment Fund 1, LLC
GTI Pennsylvania, LLC

Southwest Region
AGRiMED Industries of PA, LLC
PurePenn, LLC

Northeast Region
Holistic Farms, LLC
Cresco Yeltrah, LLC

Scores for all grower/processor applicants will be available today on the Department of Health website at www.health.pa.gov.

"The next step for the permit holders will be to ramp up their operations so they can prepare to grow medical marijuana," Collins said. "Our teams will perform a series of site inspections before the locations can be certified as operational. Once that happens, the permittees will be able to begin growing and processing medical marijuana."

The Office of Medical Marijuana received 457 total applications: 177 for growers/processors; and 280 for dispensaries.

The Medical Marijuana Program was signed into law by Governor Tom Wolf on April 17, 2016. Since that time, the department has:

The Medical Marijuana Program became effective on May 17, 2016, and is expected to be fully implemented in 2018. The program will offer medical marijuana to patients who are residents of Pennsylvania and under a physician's care for the treatment of a serious medical condition as defined by Act 16. 

Questions about the Medical Marijuana Program can be emailed to [email protected]. Information is also available on the Department of Health website at www.health.pa.gov or by following us on Facebook and Twitter.

MEDIA CONTACT: April Hutcheson, 717-787-1783 or [email protected]

Supporting documents that were provided at the news conference are available here:
Facilities by Region -
http://www.health.pa.gov/My%20Health/Diseases%20and%20Conditions/M-P/MedicalMarijuana/Documents/Phase%201%20Grower-Processor%20Permittee%20Facility%20Locations%20By%20Region.pdf

Sample Scorecard -
http://www.health.pa.gov/My%20Health/Diseases%20and%20Conditions/M-P/MedicalMarijuana/Documents/PA%20DOH%20Phase%201%20Grower-Processor%20Evaluation%20Category%20Score%20Cards.pdf

 

SOURCE Pennsylvania Department of Health


These press releases may also interest you

at 02:05
Today AstraZeneca revealed its bold ambition to deliver $80 billion in Total Revenue by 2030, up from $45.8 billion in 2023. This will be achieved through significant growth in its existing oncology, biopharmaceuticals and rare disease portfolio, and...

at 01:18
. Hansa Biopharma, "Hansa" (STOCKHOLM: HNSA), today announced data featuring imlifidase will be presented at the American Transplant Congress (ATC), the joint annual meeting of the American Society of Transplant Surgeons (ASTS) and the American...

at 01:05
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for inavolisib, an investigational oral therapy, in combination with...

at 01:05
Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today announced that in an abstract published on 14 May 2024 for the European Hematology Association 2024 Congress on SAR443579/IPH6101, submitted by...

at 00:01
Celltrion USA announced today...

at 00:01
SonarMD today presented positive results from two large, longitudinal studies evaluating several major drivers of medical costs in people living with Inflammatory Bowel Disease (IBD) ? defined as people living with ulcerative colitis or Crohn's...



News published on and distributed by: